The European Medicines Agency published highlights from the Committee for Medicinal Products for Human Use’s meeting held between 26-29 January 2026, which includes six medicines for approval at its January 2026 meeting. Also, the committee recommended another seven extensions of indication for medicines that are already authorised in the EU: Akeega, Efmody, Iclusig, Imfinzi, Kerendia, Noxafil and Opdivo.